BOSTON, Nov. 8, 2015 /PRNewswire/ -- CytomX Therapeutics
(Nasdaq: CTMX), a biopharmaceutical company developing
investigational Probody™ therapeutics for the treatment of cancer,
highlighted data during an investor event today that demonstrate
how its Probody technology improves targeting to create safer and
more effective therapies across multiple pipeline programs.
Posters containing the data can be found on the Publications
page of CytomX's website. A replay of the investor event will be
posted on the Investors and News page of CytomX's website at
8 p.m. EST today and will be
available for 60 days.
"Our research team has demonstrated preclinical proof-of-concept
for our Probody technology across a number of our pipeline
programs. We have consistently shown the ability of the platform to
create safer and more effective therapies across multiple antibody
modalities in cancer," said Michael
Kavanaugh, M.D., chief scientific officer of CytomX. "Based
on these findings, we have moved CX-072 and our CD166 programs into
IND-enabling work. In addition, our T-cell engaging bispecific data
illustrate the potential of this promising modality."
CytomX discussed preclinical results from its lead program
CX-072, a PD-L1-directed Probody therapeutic, that were initially
presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer
Immunotherapy Conference on September
16. In addition, the company presented data from its Probody
drug conjugate program directed against CD166, as well as on its
proprietary T cell-engaging Probody bispecific platform, that were
presented this week in poster sessions at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics in Boston.
Therapeutics developed with CytomX's Probody platform are
designed to be active in the tumor while sparing healthy tissue. By
restricting activity to the tumor microenvironment, Probody
therapeutics directed against both validated and novel targets
enable anti-tumor efficacy with a significantly enhanced safety
window, relative to traditional antibody-based therapies. CytomX's
preclinical pipeline of wholly-owned and partnered programs
includes Probody cancer immunotherapies, Probody drug conjugates
and T-cell engaging Probody bispecifics.
About CytomX Therapeutics
CytomX is an
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody
technology platform. The company uses the platform to create
development-stage proprietary cancer immunotherapies against
clinically-validated targets, as well as to develop first-in-class
investigational cancer therapeutics against novel targets. CytomX
believes that its Probody platform has the potential to improve the
combined efficacy and safety profile of monoclonal antibody
modalities, including cancer immunotherapies, antibody drug
conjugates and T-cell-recruiting bispecific antibodies. Probody
therapeutics are designed to take advantage of unique conditions in
the tumor microenvironment to enhance the tumor-targeting features
of an antibody and reduce drug activity in healthy tissues.
Investigational Probody therapeutics are being developed that
address clinically-validated cancer targets in immuno-oncology,
such as PD-L1 against which our clinical candidate CX-072 is
directed, as well as novel targets, such as CD-166, that are
difficult to drug without causing damage to healthy tissues, or
toxicities. In addition to its proprietary programs, CytomX is
collaborating with strategic partners including Bristol-Myers
Squibb Company, Pfizer Inc., MD Anderson Cancer Center and
ImmunoGen, Inc. For more information, visit www.cytomx.com.
Forward-Looking Statements
This press release
includes forward-looking statements. Such forward-looking
statements involve known and unknown risks, uncertainties and other
important factors that are difficult to predict, may be beyond our
control, and may cause the actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied in such
statements. Accordingly, you should not rely on any of these
forward-looking statements. Our Probody platform is in preclinical
development, and the process by which a preclinical technology
could potentially lead to an approved product is long and subject
to significant risks and uncertainties. Applicable risks and
uncertainties include those relating to our preclinical research
and development and other risks identified under the heading "Risk
Factors" included in our filings with the SEC. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Media Contacts:
Canale
Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contacts:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
Logo - http://photos.prnewswire.com/prnh/20150617/223685LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytomx-highlights-data-from-multiple-probody-pipeline-programs-at-investor-event-during-aacr-nci-eortc-conference-300174515.html
SOURCE CytomX Therapeutics